November 1, 1990Open Access
Effects of tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex on mortality in acute myocardial infarction.
Key Result
Tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex reduced the odds of early death in acute myocardial infarction by 29% and 46%, respectively.
Study Design
Type
Meta-Analysis
PICO
Population
acute myocardial infarction
Intervention / Comparator
tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex vs control
Primary Outcome
early death — OR 0.71 and OR 0.54
Main Result
Effect estimate: OR 0.71 and OR 0.54
Limitations
- Available data do not permit comparisons of the relative efficacy of these two agents with each other or with streptokinase.
Abstract
An overview of eight randomized controlled trials of tissue-type plasminogen activator (Alteplase or Duteplase) and 10 of anisoylated plasminogen streptokinase activator complex (Anistreplase) showed that the odds of early death were reduced by 29% by tissue-type plasminogen activator and 46% by anisoylated plasminogen streptokinase activator complex, with overlapping 95% confidence intervals. Although the beneficial effects of both agents are consistent and are strengthened when all the trials are considered together, the available data do not permit comparisons of the relative efficacy of these two agents with each other or with streptokinase.
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
P
P. H. Held
National Heart Lung and Blood Institute
Koon Teo
Preventive Cardiology
Salim Yusuf
Population Health Research Institute
Journals
Circulation
Actions
Institutions
National Heart Lung and Blood Institute
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...